

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Cavaleri et al. :
APPLICATION NO.: 10/829,068 : Examiner: E. Peselev
FILING DATE: 20 April 2004 : Group Art Unit: 1623
TITLE: Stable Compositions of Dalbavancin :

Via EFS

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant(s) hereby bring to the Examiner's attention the documents cited in the attached PTO-FB-A820, copies of which are enclosed (other than cited U.S. patent documents).


The Examiner is respectfully requested to consider the cited documents in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a) and to indicate such by returning a signed and initialed copy of the PTO-FB-A820 and listing the documents in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The required fee under 37 C.F.R. § 1.17(p) is being paid herewith via EFS. The Commissioner is authorized to charge any fees, which may be required, or credit any overpayment, to Account No. 16-1445.

Should there be any questions, the Examiner is invited to contact the undersigned.

Respectfully submitted,

Date: 1 May 2007



Frank W. Forman
Attorney for Applicant(s)
Reg. No. 42,547

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5669
frank.w.forman@pfizer.com